Charles Schwab’s Galectin Therapeutics GALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $540K | Buy |
116,424
+86,414
| +288% | +$224K | ﹤0.01% | 3220 |
|
|
2026
Q1 | $83.7K | Buy |
30,010
+25
| +0.1% | +$76 | ﹤0.01% | 3399 |
|
|
2025
Q4 | $125K | Sell |
29,985
-15,004
| -33% | -$79K | ﹤0.01% | 3387 |
|
|
2025
Q3 | $191K | Buy |
+44,989
| New | +$169K | ﹤0.01% | 3351 |
|
|
2025
Q2 | – | Sell |
-22,913
| Closed | -$28K | – | 3519 |
|
|
2025
Q1 | $28K | Sell |
22,913
-42,160
| -65% | -$59.1K | ﹤0.01% | 3442 |
|
|
2024
Q4 | $83.9K | Hold |
65,073
| – | – | ﹤0.01% | 3408 |
|
|
2024
Q3 | $179K | Hold |
65,073
| – | – | ﹤0.01% | 3346 |
|
|
2024
Q2 | $147K | Buy |
65,073
+47,660
| +274% | +$145K | ﹤0.01% | 3459 |
|
|
2024
Q1 | $41.6K | Hold |
17,413
| – | – | ﹤0.01% | 3382 |
|
|
2023
Q4 | $28.9K | Hold |
17,413
| – | – | ﹤0.01% | 3452 |
|
|
2023
Q3 | $33.4K | Hold |
17,413
| – | – | ﹤0.01% | 3452 |
|
|
2023
Q2 | $25.1K | Hold |
17,413
| – | – | ﹤0.01% | 3531 |
|
|
2023
Q1 | $36.6K | Hold |
17,413
| – | – | ﹤0.01% | 3406 |
|
|
2022
Q4 | $19.7K | Hold |
17,413
| – | – | ﹤0.01% | 3504 |
|
|
2022
Q3 | $29K | Hold |
17,413
| – | – | ﹤0.01% | 3441 |
|
|
2022
Q2 | $23K | Hold |
17,413
| – | – | ﹤0.01% | 3512 |
|
|
2022
Q1 | $29K | Hold |
17,413
| – | – | ﹤0.01% | 3570 |
|
|
2021
Q4 | $37K | Hold |
17,413
| – | – | ﹤0.01% | 3534 |
|
|
2021
Q3 | $68K | Hold |
17,413
| – | – | ﹤0.01% | 3415 |
|
|
2021
Q2 | $56K | Sell |
17,413
-60,075
| -78% | -$214K | ﹤0.01% | 3353 |
|
|
2021
Q1 | $169K | Sell |
77,488
-8,013
| -9% | -$18K | ﹤0.01% | 3336 |
|
|
2020
Q4 | $192K | Hold |
85,501
| – | – | ﹤0.01% | 3263 |
|
|
2020
Q3 | $229K | Sell |
85,501
-7,438
| -8% | -$20.8K | ﹤0.01% | 3137 |
|
|
2020
Q2 | $285K | Buy |
92,939
+495
| +0.5% | +$1.25K | ﹤0.01% | 3067 |
|
|
2020
Q1 | $182K | Hold |
92,444
| – | – | ﹤0.01% | 3029 |
|
|
2019
Q4 | $265K | Hold |
92,444
| – | – | ﹤0.01% | 2999 |
|
|
2019
Q3 | $340K | Buy |
92,444
+17,352
| +23% | +$62.7K | ﹤0.01% | 2937 |
|
|
2019
Q2 | $312K | Buy |
+75,092
| New | +$325K | ﹤0.01% | 2992 |
|
|
2018
Q2 | – | Sell |
-21,400
| Closed | -$102K | – | 3124 |
|
|
2018
Q1 | $102K | Hold |
21,400
| – | – | ﹤0.01% | 3038 |
|
|
2017
Q4 | $72K | Hold |
21,400
| – | – | ﹤0.01% | 3045 |
|
|
2017
Q3 | $46K | Hold |
21,400
| – | – | ﹤0.01% | 3068 |
|
|
2017
Q2 | $53K | Sell |
21,400
-130,900
| -86% | -$349K | ﹤0.01% | 3095 |
|
|
2017
Q1 | $351K | Buy |
+152,300
| New | +$230K | ﹤0.01% | 2771 |
|
|
2015
Q2 | – | Sell |
-26,400
| Closed | -$89K | – | 3101 |
|
|
2015
Q1 | $89K | Hold |
26,400
| – | – | ﹤0.01% | 3042 |
|
|
2014
Q4 | $92K | Hold |
26,400
| – | – | ﹤0.01% | 3070 |
|
|
2014
Q3 | $133K | Hold |
26,400
| – | – | ﹤0.01% | 3024 |
|
|
2014
Q2 | $365K | Buy |
+26,400
| New | +$329K | ﹤0.01% | 2769 |
|
Other funds holding GALT
WANY
Charles Schwab's GALT Position: Q2 2026 in Review
Charles Schwab increased its Galectin Therapeutics (GALT) stake by 288% in Q2 2026, buying an estimated $224K and bringing the position to 116,424 shares worth $540K. The position accounts for ﹤0.01% of the portfolio, ranked #3220.
Charles Schwab first reported a position in GALT in Q2 2014 and has held it in 37 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.
- Charles Schwab held 116,424 shares of Galectin Therapeutics worth $540K as of Q2 2026.
- Charles Schwab bought 86,414 Galectin Therapeutics shares in Q2 2026, an estimated $224K.
- Galectin Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3220 holding.
- Charles Schwab first reported a position in Galectin Therapeutics in Q2 2014 and has held it in 37 quarters since.
- 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.